| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/21/2005 | US20050085519 Controlling cell differentiation, cell proliferation; anticancer agents |
| 04/21/2005 | US20050085514 Psychological disorders; schizophrenia; anxiolytic agents; antidepressants; bipolar diseases; circadian rhythm disorders; analgesics; Parkinson's disease; Huntington's disease |
| 04/21/2005 | US20050085512 Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| 04/21/2005 | US20050085509 KInase inhibitors; antiarthritic agents; autoimmune diseases; sepsis; cachexia; Alzheimer's disease; antihistamines; thrombosis; glomerulonephritis; inflammatory bowel disorders; crohn's disese; multiple sclerosis; antitumor agents; skin disorders |
| 04/21/2005 | US20050085503 used for detecting diseases where N-acetylated alpha -linked acidic dipeptidase (NAALADase) levels are altered, effecting neuronal activity, effecting TGF- beta activity, inhibiting angiogenesis, and treating glutamate abnormalities, cancer, pain |
| 04/21/2005 | US20050085502 Phenyl-substituted imidazopyridines |
| 04/21/2005 | US20050085501 Phenyl-substituted imidazopyridines |
| 04/21/2005 | US20050085489 Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 04/21/2005 | US20050085487 Heterocyclic compounds |
| 04/21/2005 | US20050085485 Parkinson's disease; mixing with lactose and starches |
| 04/21/2005 | US20050085481 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands |
| 04/21/2005 | US20050085476 Polymerase inhibitors; antiischemic agents; brain disorders; cardiovascular disorders; antiinflammatory agents; antiarthritic agents; neurodegenerative agents; Alzheimer's disease; muscular disorders; antidiabetic agents; kidney disorders; viricides; anticancer agents; immunosuppressants |
| 04/21/2005 | US20050085475 Azabicyclylmethyl derivatives of 7,8-dihydro-1,6,9,-trioxa-3-aza-cyclopenta[a]naphthalene as 5-ht1a antagonists |
| 04/21/2005 | US20050085469 Fused bicyclic pyrimidine derivatives |
| 04/21/2005 | US20050085462 Solid oral formulation coated with hydroxypropyl methylcellulose; the polymer coating is free of polyethylene glycol |
| 04/21/2005 | US20050085461 Benzenesulfonamide derivatives |
| 04/21/2005 | US20050085460 useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease |
| 04/21/2005 | US20050085458 Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
| 04/21/2005 | US20050085457 Therapeutic quinolone compounds with 5-ht-antagonistic properties |
| 04/21/2005 | US20050085456 Compounds useful in therapy |
| 04/21/2005 | US20050085450 Oral antidepressant formulation |
| 04/21/2005 | US20050085440 Formulation |
| 04/21/2005 | US20050085423 Administering an amide ciompound ; analgesics; antiinflamamtory agents |
| 04/21/2005 | US20050085414 Novel medical use for tachykinin antagonists |
| 04/21/2005 | US20050084897 DNA encoding human vanilloid receptor VR3 |
| 04/21/2005 | US20050084552 Pharmaceutical composition of chinese herbs for treating snuffle, headache and the use thereof |
| 04/21/2005 | US20050084530 Rapid acting freeze dried oral pharmaceutical composition for treating migraine |
| 04/21/2005 | US20050084518 For producing beautiful skin and improving constipation, reducing hair loss |
| 04/21/2005 | US20050084504 Methods for treating various disorders with a neurotoxic component of a botulinum toxin |
| 04/21/2005 | US20050084486 Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| 04/21/2005 | US20050084484 Administering Lactobacillus plantarum having catalase activity and superoxide dismutase activity as an antiinflammatory agent for rheumatic diseases and psoriasis |
| 04/21/2005 | US20050084463 Antiinflammatory, antiarthritic agents, analgesics for pain caused by diabetic assoicated conditions, pneumoconiosis, angina, menstruation or cancer |
| 04/21/2005 | CA2541831A1 1-'2-(4-hydroxyphenyl)-2-hydroxyethyl!-piperidin-4-ol compounds as nmda receptor antagonists |
| 04/21/2005 | CA2541771A1 Amino acid based compositions for the treatment of pathological conditions distinguished by insufficient mitochondrial function |
| 04/21/2005 | CA2541603A1 Agent for improving mental disorders |
| 04/21/2005 | CA2541162A1 Fused lactam compounds |
| 04/21/2005 | CA2539681A1 Nucleic acid molecules encoding novel human low-voltage activated calcium channel proteins, designated - alpha 1i-1 and alpha 1i-2, encoded proteins and methods of use thereof |
| 04/21/2005 | CA2528100A1 Polymorphic forms of ziprasidone hcl and processes for their preparation |
| 04/20/2005 | EP1524270A1 Sulfur-containing proanthocyanidin oligomer composition and process for producing the same |
| 04/20/2005 | EP1524267A1 Substituted benzylaminoalkylene heterocycles |
| 04/20/2005 | EP1524266A1 Pharmaceutical composition |
| 04/20/2005 | EP1524265A1 Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| 04/20/2005 | EP1524263A1 prodrugs containing cycloalkene derivatives |
| 04/20/2005 | EP1523982A2 Plenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders |
| 04/20/2005 | EP1523556A1 Methods of treating conditions associated with an edg-1 receptor |
| 04/20/2005 | EP1523549A2 Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| 04/20/2005 | EP1523541A1 A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 04/20/2005 | EP1523488A1 Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof |
| 04/20/2005 | EP1523486A2 Tetracyclic arylsulfonyl indoles having serotonin receptor affinity |
| 04/20/2005 | EP1523480A2 Derivatives of 3-guanidinocarbonyl-1-heteroaryl-pyrrole, process for their preparation and their pharmaceutical use |
| 04/20/2005 | EP1523473A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 04/20/2005 | EP1523471A1 Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| 04/20/2005 | EP1523469A1 Cinnamide derivatives |
| 04/20/2005 | EP1523336A1 Targeted agents for nerve regeneration |
| 04/20/2005 | EP1523335A2 Injectable depot formulation comprising crystals of iloperidone |
| 04/20/2005 | EP1523326A2 Insulin-associated peptides with effects on cerebral health |
| 04/20/2005 | EP1523323A2 Reagents and methods for smooth muscle therapies |
| 04/20/2005 | EP1523312A1 Use of a rhein in a therapeutic treatment requiring a rise in the rate of heme oxygenase |
| 04/20/2005 | EP1523309A2 Nmda receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau |
| 04/20/2005 | EP1458355A4 Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol |
| 04/20/2005 | EP1448547B1 Pyridine derivatives as nmda receptor ligands |
| 04/20/2005 | EP1392316B1 Benzo[d]azepine derivatives as 5-ht6 receptor antagonists. |
| 04/20/2005 | EP1373249B1 Imidazolidine derivatives, their preparation, and their use as antiinflamatory agent |
| 04/20/2005 | EP1365737B1 Stable salts of o-acetylsalicyclic with basic amino acids |
| 04/20/2005 | EP1349843B1 Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| 04/20/2005 | EP1317306B1 Transdermal electrotransport device and method for manufacturing same |
| 04/20/2005 | EP1307425B1 Novel n-(2-phenyl-3-aminopropyl)naphtamides |
| 04/20/2005 | EP1283839B1 Adenosine a2a receptor antagonists |
| 04/20/2005 | EP1254133B1 Indol-3-yl derivatives and their use as integrin inhibitors |
| 04/20/2005 | EP1252158B1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| 04/20/2005 | EP1226110B1 Bicyclic amino acids as pharmaceutical agents |
| 04/20/2005 | EP1213290B1 Dihydrobenzofuran derivatives, process for the preparation thereof and agents |
| 04/20/2005 | EP1196417B1 1,2,3,4,5,6-HEXAHYDROAZEPINO 4,5-b]INDOLES CONTAINING ARYLSULFONES AT THE 9-POSITION |
| 04/20/2005 | EP1185649B1 The myostatin gene promoter and inhibition of activation thereof |
| 04/20/2005 | EP1177185B1 4, 5, 6, 7-tetrahydroindazole derivatives as antitumor agents |
| 04/20/2005 | EP1152751B1 Desoxypeganine transdermal therapeutic system |
| 04/20/2005 | EP1143977B1 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 04/20/2005 | EP1135168B1 Peptides carrying substances across the blood brain barrier |
| 04/20/2005 | EP1129077B1 Fluorinated 3,4-dihydroquinoline derivatives used as nos inhibitors |
| 04/20/2005 | EP1015431B1 2-aminopyridines as inhibitors of cyclooxygenase-2 |
| 04/20/2005 | EP0775213B1 Adenovirus comprising a gene coding for glutathion peroxidase |
| 04/20/2005 | EP0721455B9 Tetrahydropyridine-(or 4-hydroxypiperidine)alkylazoles having an affinity for sigma and/or 5ht1a receptors |
| 04/20/2005 | CN1608069A Selective androgen receptor modulators and methods for their identification, design and use |
| 04/20/2005 | CN1608067A Pyrrolopyrimidines as phosphodiesterase vii inhibitors |
| 04/20/2005 | CN1608065A Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase and pharmaceutical compositions containing the compounds |
| 04/20/2005 | CN1608064A Novel compounds |
| 04/20/2005 | CN1608062A Salt forms of e-2-methoxy-n-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| 04/20/2005 | CN1608061A Therapeutic isoquinoline compounds |
| 04/20/2005 | CN1608060A Diaryl 1, 2, 4-triazole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/20/2005 | CN1608059A Bipyridyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/20/2005 | CN1608057A Method for the preparation of citalopram |
| 04/20/2005 | CN1608056A Carboxylic acid derivative compounds and agents comprising the compounds as active ingredient |
| 04/20/2005 | CN1608055A Compounds for the treatment of metabolic disorders |
| 04/20/2005 | CN1608054A Therapeutic quinolone compounds with 5-HT-antagonistic properties |
| 04/20/2005 | CN1608050A Piperazine derivative |
| 04/20/2005 | CN1607960A Glycoprotein compositions |
| 04/20/2005 | CN1607959A Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells |
| 04/20/2005 | CN1607957A Modulation of excitable tissue function by peripherally administered erythropoietin |
| 04/20/2005 | CN1607954A Pregnane steroids for use in the treatment of cns dysfunction |
| 04/20/2005 | CN1607950A A liquid pharmaceutical formulation comprising nicotine for the administration to the oral cavity |